Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Pharma
FDA signs off on depression label expansion for J&J's Caplyta
J&J's Caplyta can now unlock the lucrative major depressive disorder market as an adjunctive treatment to antidepressants.
Zoey Becker
Nov 6, 2025 8:43am
Axsome will begin trial this year in MDD with daytime sleepiness
Apr 1, 2025 4:40pm
Teva agrees with Axsome to keep generic off market until 2038
Feb 10, 2025 11:28am
How J&J CEO broke a stalemate and won Intra-Cellular in M&A push
Feb 7, 2025 11:24am
FDA signs off on Johnson & Johnson's Spravato as a monotherapy
Jan 21, 2025 3:23pm
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
